📊 FULC Key Takeaways
Is Fulcrum Therapeutics, Inc. (FULC) a Good Investment?
Fulcrum Therapeutics is a pre-revenue biopharmaceutical company with severe cash burn and no commercial revenue, indicating it has not successfully brought any products to market. With annual operating losses of $84.8M and free cash flow of -$60.4M, the company is in a critical runway phase despite maintaining $197.5M in cash reserves. The complete absence of revenue combined with substantial operating losses demonstrates the company faces significant execution risk in bringing pipeline programs to commercialization.
Fulcrum Therapeutics shows very weak operating fundamentals: revenue fell to zero, operating losses remain large, and free cash flow is deeply negative. The balance sheet is unusually strong for a development-stage biotech, with substantial cash, no meaningful debt, and very high liquidity, but absent a clear revenue base or improving loss trajectory, the business currently relies on cash runway and pipeline execution rather than durable operating strength.
Why Buy Fulcrum Therapeutics, Inc. Stock? FULC Key Strengths
- Strong cash position of $197.5M provides runway for R&D operations
- No long-term debt obligations reduces financial leverage risk
- Excellent liquidity position with 27.4x current ratio ensures near-term solvency
- Significant stockholders equity of $349M provides balance sheet cushion
- Strong balance sheet with $197.53M of cash and $349.00M of equity against only $17.28M of liabilities
- No meaningful leverage, with debt/equity at 0.00x, reducing financial distress risk
- Very high liquidity, with current and quick ratios of 27.40x, supporting near-term funding needs
FULC Stock Risks: Fulcrum Therapeutics, Inc. Investment Risks
- Zero revenue with $84.8M annual operating losses indicates no approved commercial products
- Negative free cash flow of $60.4M annually means cash reserves deplete rapidly
- Diluted EPS of -$1.18 with extreme YoY deterioration shows persistent losses
- Pre-revenue status means company has not demonstrated ability to commercialize any assets
- Current cash burn rate suggests approximately 3.3 years of runway before cash depletion
- ROE of -21.5% and ROA of -20.4% indicate significant shareholder value destruction
- Revenue collapsed to $0.00, indicating no current commercial or collaboration income support
- Large ongoing losses, including -$84.77M operating income and -$60.38M free cash flow, show continued cash consumption
- Growth quality is weak because the business is not yet self-funding and future performance is highly dependent on pipeline and execution outcomes
Key Metrics to Watch
- Time to next major clinical milestone or regulatory approval
- Monthly cash burn rate trends and updated runway estimates
- Pipeline program advancement and clinical trial progress updates
- Quarterly revenue generation from any approved products
- Quarterly operating cash flow and cash burn relative to cash balance
- Any return of recurring revenue and the trend in operating loss
Fulcrum Therapeutics, Inc. (FULC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 27.40x current ratio provides a solid financial cushion.
FULC Profit Margin, ROE & Profitability Analysis
FULC vs Healthcare Sector: How Fulcrum Therapeutics, Inc. Compares
How Fulcrum Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fulcrum Therapeutics, Inc. Stock Overvalued? FULC Valuation Analysis 2026
Based on fundamental analysis, Fulcrum Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fulcrum Therapeutics, Inc. Balance Sheet: FULC Debt, Cash & Liquidity
FULC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fulcrum Therapeutics, Inc.'s revenue has grown significantly by 317% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.16 indicates the company is currently unprofitable.
FULC Revenue Growth, EPS Growth & YoY Performance
FULC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $6.8M | $0.11 |
| Q2 2025 | N/A | -$17.3M | $-0.28 |
| Q3 2024 | N/A | $6.8M | $0.11 |
| Q2 2024 | $880.0K | -$23.8M | $-0.38 |
| Q1 2024 | N/A | -$24.8M | $-0.41 |
| Q3 2023 | $759.0K | -$23.7M | $-0.39 |
| Q1 2023 | $295.0K | -$23.8M | $-0.38 |
| Q3 2022 | $1.2M | -$17.0M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fulcrum Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
FULC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fulcrum Therapeutics, Inc. (CIK: 0001680581)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FULC
What is the AI rating for FULC?
Fulcrum Therapeutics, Inc. (FULC) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FULC's key strengths?
Claude: Strong cash position of $197.5M provides runway for R&D operations. No long-term debt obligations reduces financial leverage risk. ChatGPT: Strong balance sheet with $197.53M of cash and $349.00M of equity against only $17.28M of liabilities. No meaningful leverage, with debt/equity at 0.00x, reducing financial distress risk.
What are the risks of investing in FULC?
Claude: Zero revenue with $84.8M annual operating losses indicates no approved commercial products. Negative free cash flow of $60.4M annually means cash reserves deplete rapidly. ChatGPT: Revenue collapsed to $0.00, indicating no current commercial or collaboration income support. Large ongoing losses, including -$84.77M operating income and -$60.38M free cash flow, show continued cash consumption.
What is FULC's revenue and growth?
Fulcrum Therapeutics, Inc. reported revenue of $0.0.
Does FULC pay dividends?
Fulcrum Therapeutics, Inc. does not currently pay dividends.
Where can I find FULC SEC filings?
Official SEC filings for Fulcrum Therapeutics, Inc. (CIK: 0001680581) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FULC's EPS?
Fulcrum Therapeutics, Inc. has a diluted EPS of $-1.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FULC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Fulcrum Therapeutics, Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FULC stock overvalued or undervalued?
Valuation metrics for FULC: ROE of -21.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FULC stock in 2026?
Our dual AI analysis gives Fulcrum Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FULC's free cash flow?
Fulcrum Therapeutics, Inc.'s operating cash flow is $-60.1M, with capital expenditures of $314.0K.
How does FULC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -21.5% (avg: 15%), current ratio 27.40 (avg: 2).